Natural Killer (NK) cell treatments are not readily accessible to patients due to persistent manufacturing complexities, scalability issues, and challenges in delivery. Cellistic's iPSC-based allogeneic Echo™-NK Manufacturing Platform breaks down these barriers by enabling therapeutic developers to manufacture safe, consistent, and cost-efficient off-the-shelf NK cell therapies at scale.
In her latest article, Anne-Sophie Lebrun, MSAT Director, provides an in-depth look at the Echo™-NK platform's comprehensive manufacturing process, specifically designed to tackle the scientific and logistical challenges that impede NK cell therapies with a cost effective approach.
Highlights of the insights include:
- Unit Operations Overview: A detailed look at the Unit Operations (UOP) from GMP Master Cell Bank to final drug product release, highlighting volume expansion capabilities and the specific technologies utilized at each step.
- Innovative Features and Technologies: An exploration of key innovations, including a feeder-free culture system that enhances both safety and consistency, as well as advanced bioreactor technologies that ensure compliance with GMP standards.
- Compliance and Proven Performance: Insight into critical performance metrics and results that validate the efficacy and reliability of the Echo™-NK platform, underscoring its potential as a commercially viable solution for NK cell therapy manufacturing.
Get all the technical details—download the article to enhance your understanding of the Echo™-NK platform!
